false 0001736243 0001736243 2024-06-17 2024-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 17, 2024

 

Acurx Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware  001-40536  82-3733567
(State or other jurisdiction
of incorporation)		  (Commission
File Number)		 

(IRS Employer
Identification No.)

 

259 Liberty Avenue, Staten Island, NY 10305

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (917) 533-1469

 

Not applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol		   Name of each exchange
on which registered
Common Stock, par value $0.001 per share   ACXP   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

At the close of business on April 26, 2024, the record date of the Annual Meeting of Acurx Pharmaceuticals, Inc. (“we”, “us” and “our”) held on June 17, 2024 (the “Annual Meeting”), there were 15,823,102 shares of common stock outstanding and entitled to vote. At the Annual Meeting, the holders of 10,648,350 shares of our common stock, or approximately 67.29% of our outstanding shares of common stock, were represented in person or by proxy and, therefore, a quorum was present. At the Annual Meeting, our stockholders considered two proposals, which are described briefly below and in more detail in our definitive Proxy Statement filed with the Securities and Exchange Commission on April 29, 2024. The final voting results for each proposal are set forth below.

 

Proposal 1 - Election of Directors

 

Our stockholders elected the following directors as Class III directors to hold office until the 2027 Annual Meeting of stockholders by the following votes:

 

Nominees  Shares Voted
For		  Shares
Withheld		  Broker
Non-Votes
Robert J. DeLuccia  5,235,276  576,861  4,836,213
Joseph C. Scodari  4,807,715  1,004,422  4,836,213
James Donohue  4,810,817  1,001,320  4,836,213

 

Proposal 2 - Ratification of Independent Registered Public Accounting Firm

 

Our stockholders ratified the appointment of CohnReznick LLP as our independent auditors for the fiscal year ending December 31, 2024 by the following votes:

 

Shares Voted For  Shares Voted Against  Abstentions  Broker Non-Votes
10,542,955  69,261  36,134  —

 

 

 

  

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.

 

  Acurx Pharmaceuticals, Inc.
Date: June 17, 2024    
  By: /s/ David P. Luci
  Name: David P. Luci
  Title: President and Chief Executive Officer

 

 

v3.24.1.1.u2
Cover
Jun. 17, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 17, 2024
Entity File Number 001-40536
Entity Registrant Name Acurx Pharmaceuticals, Inc.
Entity Central Index Key 0001736243
Entity Tax Identification Number 82-3733567
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 259 Liberty Avenue
Entity Address, City or Town Staten Island
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10305
City Area Code 917
Local Phone Number 533-1469
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ACXP
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Grafico Azioni Acurx Pharmaceuticals (NASDAQ:ACXP)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di Acurx Pharmaceuticals
Grafico Azioni Acurx Pharmaceuticals (NASDAQ:ACXP)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di Acurx Pharmaceuticals